Absence of expected improvement by mid-protocol (4-6 weeks) warrants reassessment
Treatment eligibility, formulation, dosage, administration schedule, monitoring, program length and cost are determined during consultation with a licensed healthcare provider
Children aged 412 years were diagnosed with ASD according to DSM criteria, both boys and girls were included, and the study explicitly excluded participants with major psychiatric comorbidities such as ADHD, depressions, bipolar disorder, anxiety disorders, epilepsy, severe intellectual disabilities, or recent antipsychotic use, ensuring relative homogeneous sample focused on irritability
This significantly increases the bioavailability and effectiveness of the supplement
All providers are background-checked and carry current certifications